Niagen Bioscience Announces Participation in Upcoming Investor Conferences

About this update from Niagen Bioscience, Inc.

LOS ANGELES, May 08, 2026 --( BUSINESS WIRE )-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will participate in the following upcoming conferences: 31st Annual Sohn Investment Conference 4th Annual Benchmark Consumer One-On-One Conference If you would like to schedule a one-on-one meeting with the Niagen management team during either conference, please contact your respective conference representative or email [email protected] . For additional information on Niagen Bioscience, visit www.niagenbioscience.com . About Niagen Bioscience: Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience ™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality. Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age. At the heart of its clinically proven product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD+ booster available. Niagen powers the Company’s consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at www.truniagen.com ), and Niagen™ Plus, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products ( www.niagenplus.com ). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com , where copies of press releases, news, and financial information are regularly published. † Based on revenue per largest U.S. e-commerce marketplace (Jan. 2025 – Dec. 2025) View source version on businesswire.com: https://www.businesswire.com/news/home/20260508658207/en/ Contacts Niagen Bioscience Media Contact: Kendall Knysch, Senior Director of Media Relations & Partnerships 310.405.5227 [email protected] Niagen Bioscience Investor Relations Contact: Valter Pinto, Managing Director KCSA Strategic Communications 212.896.1254 [email protected]

View stock analysis, news, and events for Niagen Bioscience, Inc.